LivaNova (LIVN) Capital Expenditures (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | LivaNova | 4.03 Bn | 3.45 Bn | 243.75 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -55.67% |
| Dec 31, 2025 | 40.88% |
| Sep 30, 2025 | 51.05% |
| Jun 30, 2025 | 40.38% |
| Mar 31, 2025 | 3.69% |
| Dec 31, 2024 | -42.66% |
| Sep 30, 2024 | 49.28% |
| Jun 30, 2024 | 90.00% |
| Mar 31, 2024 | -50.48% |
| Dec 31, 2023 | 48.19% |
| Sep 30, 2023 | 54.06% |
| Jun 30, 2023 | -26.36% |
| Mar 31, 2023 | -15.86% |
| Dec 31, 2022 | 51.20% |
| Sep 30, 2022 | -1.40% |
| Jun 30, 2022 | 17.49% |
| Mar 31, 2022 | -31.25% |
| Dec 31, 2021 | 131.89% |
| Sep 30, 2021 | -48.91% |
| Jun 30, 2021 | -22.12% |
| Mar 31, 2021 | 24.94% |
| Dec 31, 2020 | -37.28% |
| Sep 30, 2020 | 12.10% |
| Jun 30, 2020 | 8.85% |
| Mar 31, 2020 | 8.96% |
| Dec 31, 2019 | 31.39% |
| Sep 30, 2019 | 18.79% |
| Jun 30, 2019 | -11.95% |
| Mar 31, 2019 | -55.39% |
| Dec 31, 2018 | 8.77% |
| Sep 30, 2018 | 78.19% |
| Jun 30, 2018 | 13.58% |
| Mar 31, 2018 | -34.53% |
| Dec 31, 2017 | -1.67% |
| Sep 30, 2017 | 23.43% |
| Jun 30, 2017 | -2.76% |
| Mar 31, 2017 | -19.80% |
| Dec 31, 2016 | -23.13% |
| Oct 18, 2015 | 48.28% |
| Jul 24, 2015 | 140.69% |